Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2020-10-11 Board/Management Inform…
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
CEO appointment 2 pages 136.0KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 12th October 2020 regarding the appointment of a new CEO, Matthew Golden, including his background, terms of appointment, and changes in executive roles. It does not contain financial statements, earnings data, or detailed management discussion. It is an announcement of a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or financial disclosure.
2020-10-11 English
Ceasing to be a substantial holder 2 pages 716.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001. It details changes in relevant interests and shareholdings of a substantial holder in the company Lifespot Health Ltd. This type of filing is a notification of changes in significant share ownership levels, specifically when a holder ceases to be substantial. It is not a financial report, earnings release, or management report, but a regulatory notification about shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief announcement or a report publication notice but a formal regulatory filing of shareholding changes.
2020-10-11 English
Change in substantial holding 2 pages 590.7KB
Regulatory Filings
2020-10-07 English
Private Placement and Market update 2 pages 137.2KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement dated 2 October 2020 regarding a private placement of shares raising $960,000. It details the use of funds, the number of shares issued, and references shareholder approval from a previous AGM. The content focuses on capital raising and market update information, including strategic use of proceeds and operational updates. There are no financial statements or detailed financial performance data presented, nor is this a transcript, report, or regulatory certification. The document fits the definition of a Capital/Financing Update (CAP) as it announces fundraising and capital structure changes.
2020-10-01 English
Appendix 2A 14 pages 220.4KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance of new shares via private placement and the request for these securities to be quoted. This is a regulatory announcement related to capital raising and securities quotation, not a financial report or earnings release. It is not a full report but a formal notification to the exchange about new securities issuance and quotation. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement of a report but a substantive filing about capital changes.
2020-10-01 English
Reinstatement to Official Quotation 1 page 88.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from ASX regarding the reinstatement to official quotation of Lifespot Health's securities following a suspension. It references a capital raising announcement but does not contain financial data or detailed report content. The document is short (681 characters) and serves as a regulatory announcement rather than a full report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2020-10-01 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.